| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: HLCS |
| Security Type |
Common Stock |
| Lead Underwriter |
UBS Investment Bank |
| Days In Registration |
84 |
| Date Filed |
28-Feb-2007 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Helicos BioSciences, headquartered in Cambridge, Massachusetts, is a pioneer in next-generation sequencing technologies. The Company is developing a unique genetic analysis platform based on an innovative approach called true single molecule sequencing. The technology platform under development is designed to sequence individual DNA or RNA molecules with unprecedented performance. The technology consists of an instrument system, called the HeliScope, the associated single-molecule assay reagents, and software; The platform will have extensive capabilities in basic and translational research, pharmaceutical R&D and diagnostic development applications. The company was founded in 2003. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
20.52M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
5.4M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
5.4M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
810.0K |
| File Amount |
$75.6M |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
Current Filing Information
(Amended 23-May-2007) |
|
US |
|
Shares Filed |
5.4M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.4M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$56.7M |
| · % Change from Original |
-25.0 |
| File Price Range |
$11.00 - $10.00 |
| File Mid Price |
$10.50 |
|
